Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339052 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
A Phase 2 study, sponsored by Patrick Y. Wen, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01339052 is a Phase 2 study that has completed, run by Patrick Y. Wen, MD. The registered enrollment target is 65 participants.
The verdict
NCT01339052, a Phase 2 study, has completed, sponsored by Patrick Y. Wen, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
BKM120 is a newly discovered drug that has been used in other research studies. Information from those other research studies suggests that BKM120 may help to slow or stop the growth of malignant gliomas. The purpose of this study is to see how well BKM120 works in patients with malignant gliomas. Patients on this study will be treated in two groups: patients who are going to receive surgery and those who will not receive surgery. This study is trying to determine how effective BKM120 is in stopping cancer cells from growing. For patients receiving surgery the research will also try to determine if an effective level of BKM120 can penetrate the brain before surgery.
Interventions
- PROCEDURE Surgery
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2011-09 |
| Est. Completion | 2019-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339052
The ClinicalTrials.gov registry entry for NCT01339052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Y. Wen, MD, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.
NCT01339052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01339052 about?
NCT01339052 is a clinical study titled "Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma". BKM120 is a newly discovered drug that has been used in other research studies. Information from those other research studies suggests that BKM120 may help to slow or stop the growth of malignant gliomas. The purpose of this study is to see how well BKM120 works in patients with malignant gliomas. P...
What is the current status of trial NCT01339052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2011-09. Estimated completion is 2019-02.
What interventions are being tested in trial NCT01339052?
The interventions under investigation include: Surgery (PROCEDURE), BKM120 (DRUG).
Who is sponsoring clinical trial NCT01339052?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.